From The Editor

  1. Gene Therapy Development Crosses A Digital Divide 9/8/2020

    Mainframe to digital: NeuBase Therapeutics Chairman, CEO, & Founder Dietrich A. Stephan, Ph.D. says we’ve reached a digitally-enabled inflection point in disease therapy development, and that we're making rapid progress aided by big data and machine learning.

  2. Does RNAi Have A Future Beyond Liver Disease? 9/4/2020

    On the heels of his company's RNA interference IP buying spree, Arrowhead Pharmaceuticals CEO Dr. Christopher Anzalone seeks to prove the merits of RNAi in diseases beyond the liver.

  3. So You Want To Be A Chief Medical Officer? 8/13/2020

    BioProcess Online caught up with Dr. Loretta Itri, veteran CMO at Immunomedics, fresh on the heels of her 18th drug approval. The ensuing conversation on her mastery of the multifaceted role serves as a blueprint for aspiring chief medical officers.

  4. The Organizational Nuance Of An Immuno-Oncology Startup 8/11/2020

    How Jeff Wolf pieced Heat Biologics together before immuno-oncology was en vogue, and how the foundation he built is supporting the company’s growth today.

  5. Maintaining Lab Operations Amid Coronavirus Restrictions 8/7/2020

    Obsidian Therapeutics CEO Dr. Paul Wotton developed a novel solution to the workforce and resource disruption caused by COVID-19 social distancing restrictions. Here, he shares insight on the features of the application, which he's made available to other biotechs cost-free.

  6. COVID-19 And The Next Chapter In Ansun’s Turnaround Story 8/4/2020

    How Dr. Nancy Chang turned an embattled company in financial freefall and on the heels of clinical failure into a leading clinical-stage biopharma—and how the disruption of a global pandemic made Ansun Biopharma a formidable contender in the treatment of COVID-19.

  7. Advocates For AI In The Laggard Life Sciences 8/3/2020

    A team at Xavier Health is taking an unbiased lead on the adoption of artificial intelligence in the life sciences. Here are some biopharma use cases, and a peek at the progress they'll report on at this month's Xavier AI Summit.

  8. Big Data: Accelerating EXUMA Biotech In The Race To Rapid CAR-T Therapy 8/3/2020

    In pre-clinical studies using a modified lentiviral vector—whereby T cell genes are modified using a lentivirus—EXUMA Biotech has demonstrated that autologous vein-to-vein CAR-T could be possible in just 6 hours time. In 2021, the company plans to prove the viability of its Rapid Point of Care (rPOC) platform in the clinic. 

  9. Breaking Down The Science / Finance Language Barrier 8/3/2020

    Startup biotechs run on money and science. When communication between finance pros and scientists gets lost in translation, cash runways tend to truncate. Here, Athersys CFO Ivor Macleod draws light on a problem inherent to—but not often directly addressed by—new and emerging biotech organizations.

  10. The Compounded Risk Of Early-Stage Biopharma Licensing Deals 6/25/2020

    For emerging biopharma firms, licensing options can equal a boon to the business when cash runways are short and financing options run thin. But, there’s a catch. Most licensed candidates fail. And, according to a new paper, rushed licensing deals on the heels of phase 3 clinical failures only compound the disappointment.